Search

Human papilloma virus can infect any mucous of the body and to cause cancer of the uterine cervix. The last recommendation suggests making the Papanicolaou combined with a test for detection of human papillomavirus with a frequency interval of 3 years, since it grants greater information and fidelity of the result. The detection studies should begin at the age of 21 years and should stop the pursuit at 65 years age. Until recently specific treatments did not exist on this burden, but have arisen some drugs that have demonstrated good effectiveness to cure the infection for human papilloma virus, as the glycirrhicinic acid that has demonstrated less adverse effects, as well as the possibility of its systemic employment, that allows to arrive to the lesions with difficult to approach. The medical recommendations should be in constant revision, since the trial of the clinical can modify the interpretation, for what it is necessary to personalize each patient treatment. [ABSTRACT FROM AUTHOR]

Objective: To analyze the short-term efficacy and safety over menopausal symptoms of three low-dose continuous sequential 17β-estradiol (E)/progesterone (P) parental monthly formulations using novel non-polymeric microspheres. Methods: This was a multicenter, randomized, single blinded study in which peri- and postmenopausal women were assigned to receive a monthly intramuscular injection of 0.5 mg E + 15 mg P (Group A,n = 34), 1 mg E + 20 mg P (Group B,n = 24) or 1 mg E + 30 mg P (Group C,n = 26) for 6 months. Primary efficacy endpoints included mean change in the frequency and severity of hot flushes and the effect over urogenital atrophy symptoms at 3 and 6 months. Safety variables included changes in the rate of amenorrhea, endometrial thickness and histopathology, and local and systemic adverse events. Results: Compared to baseline at month 6, the three treatment schemes significantly decreased the rate of urogenital atrophy symptoms and the frequency (mean number per day) and severity (mean number graded as moderate and severe per month) of hot flushes. No differences in studied efficacy parameters were observed between studied groups at baseline or at the end of the study. For all groups the most frequent adverse event was pain at the injection site; however they were all rated as mild. At the end of the study peri- and postmenopausal women displayed no significant changes in endometrial thickness or histopathology in all treated groups. The rate of amenorrhea at the end of the study decreased for all studied groups yet was less evident among postmenopausal women as compared to perimenopausal ones. Conclusions: The three low-dose continuous sequential intramuscular monthly treatments of E/P using novel microsphere technology were effective at reducing menopausal symptoms at short-term with a low rate of adverse events. More long-term and comparative research is warranted to support our positive findings. [ABSTRACT FROM AUTHOR]